Biochemistry

Bio-Based Itaconic Acid Market | Key Opportunities, Trends, Business Demand And Key Players Analysis | Itaconix Corporation, Qingdao Kehai…

Bio-Based Itaconic Acid Market report helps to Analys Market by critical success factors (CSFs) And industry dynamics that mainly covers drivers and restraints, market segmentation, & value chain analysis, key opportunities, application and technology outlook. The report also provides regional or geographical insight, country-level analysis, key company profiles, competitive landscape, and company market share analysis. This market research report deeply analyses the potential of the market with respect to current scenario and the future prospects by taking into view numerous industry aspects.

About Bio-Based Itaconic Acid Market:

Bio-based itaconic acid market is expected to grow at a rate of 5.50% for the forecast period of 2020 to 2027. Data Bridge Market Research report on bio-based itaconic acid market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the markets growth.The changing trend towards eco-friendly products due to growing awareness regarding green house emissions will help impact the bio-based itaconic acid market growth in the forecast period.

Download Free Sample Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bio-based-itaconic-acid-market

The Bio-Based Itaconic Acid Market report is an appropriate compilation of all necessary data for the residential, industrial and commercials buyers, manufacturers, governments, and other stakeholders to implement their market-centric tactics in line with the projectedalsobecause theprevailing trendswithin theBio-Based Itaconic Acid Market.

leadingPlayers Covered in Bio-Based Itaconic Acid Market Report :

The major players covered in the bio-based itaconic acid market report are Thermo Fisher Scientific., Itaconix Corporation, Qingdao Kehai Biochemistry Co., LTD., AEKYUNG PETROCHEMICAL Co., Ltd, Zhejiang Guoguang Biochemistry Co.,Ltd., Spectrum Ultimate Chem India Pvt. Ltd, Alpha Chemika, Haihang Industry Co., Ltd, Ronas Chemicals Ind. Co., Ltd., Hefei TNJ Chemical Industry Co.,Ltd., Alfa Aesar, Merck KGaA, Choice Organochem Llp., FUSO CHEMICAL CO., LTD., Henan Haofei Chemical Co.,Ltd., Chemical Manufacturing Corp and FUJIFILM Wako Pure Chemical Corporation, among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Key Questions Answered by the Report

Get More Insight Before Buying @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bio-based-itaconic-acid-market

This report makes it easy to know about the market strategies that are being adopted by the competitors and leading organizations.An influential business report also provides the understanding of the most affecting driving and restraining forces in the market and its impact on the global market.

Highlights of the Report:

Get Table of Contents with Charts, Figures & Tables @https://www.databridgemarketresearch.com/toc/?dbmr=global-bio-based-itaconic-acid-market

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

Tel: +18883872818

corporatesales@databridgemarketresearch.com

Read the rest here:
Bio-Based Itaconic Acid Market | Key Opportunities, Trends, Business Demand And Key Players Analysis | Itaconix Corporation, Qingdao Kehai...

Biochemistry

Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer – Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a presentation by Memorial Sloan Kettering Cancer Center (MSK) at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) to discuss the Resolution ctDx Lung, a laboratory-developed test (LDT) developed by Resolution Bioscience.

The presentation titled Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer will present evidence for the clinical utility of Resolution ctDx Lung in detecting actionable mutations in non-small cell lung cancer (NSCLC) patients.

Previous findings have supported the clinical utility of the Resolution ctDx Lung for accurately selecting patients for targeted therapies.1 The latest study, involving the largest prospective liquid biopsy cohort (>1,000 patients) with 34 years of survival data, demonstrates that cell-free DNA guided targeted therapies help result in better overall survival.

This is the first and largest prospective study of ctDNA guided therapy to show an overall survival benefit in patients with lung cancers, providing evidence for the utility of liquid biopsy in clinical practice, said Bob Li, MD, PhD, MPH, Co-Director of the Thoracic Liquid Biopsy Program at MSK.

This large cohort highlights the utility of the Resolution ctDx Lung in helping guide therapy selection to improve patient outcomes, said Mark Li, CEO of Resolution Bioscience, now a part of Agilent. Significantly, the study highlighted important differences between liquid biopsies and tissue testing, including faster turnaround to reporting, while providing the benefits of guided targeted therapy."

The success of Resolution ctDx Lung further strengthens Agilent's ability to deliver precision oncology testing assays for patients worldwide and demonstrates the company's commitment as a partner in the development of powerful new clinical diagnostics solutions to expand the fight against cancer.

Resolution Bioscience is dedicated to developing a highly sensitive, non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring for patients around the world. The company has developed core technology for circulating cell-free DNA NGS analysis. Resolution Biosciences Liquid Biopsy assays are powered by the companys cell-free DNA (cfDNA) analysis platform, which includes targeted capture next-generation sequencing (NGS) biochemistry and tightly coupled, cloud-based bioinformatics. The Resolution Bioscience homologous recombination deficiency (HRD) assay has received Breakthrough Device Designation from the U.S. Food and Drug Administration.

References:

About Agilent Technologies

Agilent is a leader in life sciences, diagnostics, and applied chemical markets, delivering innovative technology solutions that provide trusted answers to researchers most challenging scientific questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at http://www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Read the original:
Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer - Business Wire

Biochemistry

Stablix Therapeutics Launches with $63 Million Series A Financing – BioSpace

--Versant Ventures leads investment in first-in-category company with targeted protein stabilization platform --

--Foundational know-how establishes leadership in the field--

NEW YORK--(BUSINESS WIRE)-- Stablix Therapeutics, a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS), today announced a $63 million Series A financing led by founding investor Versant Ventures together with NEA, Cormorant, Euclidean Capital and Alexandria Real Estate Equities.

Many inherited and acquired diseases are caused by insufficient levels of specific proteins. With inherited diseases such as cystic fibrosis, mutations in the CFTR gene produce a protein that remains functional but is subject to excessive ubiquitination, leading to its rapid degradation via the proteasome. Excess ubiquitination is also a feature of cancer, where E3 ubiquitin ligases enzymes that add ubiquitin to proteins are frequently upregulated or amplified, driving the degradation of tumor suppressor proteins.

Until now, it has not been possible to inhibit the ubiquitin-proteasome system in a target-selective manner. Stablixs RESTORED platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. The company initially is leveraging the platform to develop programs to treat rare diseases, cancer and immunological disorders.

Stablix possesses a first-in-category platform that can restore protein stability and function in a target-selective manner, said Carlo Rizzuto, Ph.D., partner at Versant and acting CEO of Stablix. We are very pleased to launch this company to address this important therapeutic white space for numerous devastating diseases.

Targeted Protein Stabilization (TPS)

Protein stabilization can be thought of as the inverse of protein degradation. The underlying concept of augmenting protein stabilization has been validated in nature. Many viruses encode their own E3 ligases and deubiquitinases to coopt the ubiquitin-proteasome system as part of their life cycles. This demonstrates that the system can be manipulated via exogenous intervention.

The therapeutic value of augmenting protein stabilization has also been demonstrated with proteasome inhibitors. These inhibitors are potent cancer therapeutics but have also been profiled for activity in Mendelian diseases in multiple animal and patient studies. In these studies, proteasome inhibitors were able to increase levels of deficient proteins across a range of targets and organ systems. However, because proteasome inhibitors globally inhibit protein degradation in a non-specific manner, their use outside of oncology is limited by poor tolerability, highlighting the need for targeted approaches.

The Stablix platform originated in the laboratory of Henry Colecraft, Ph.D., John C. Dalton Professor of Physiology and Cellular Biophysics at Columbia University. Co-founders Dr. Colecraft and Scott Kanner, Ph.D., developed an approach to selectively recruit deubiquitinases (DUBs) to proteins of interest. Their pioneering work demonstrated the functional rescue of CFTR and of a second target, KCNQ1, a gene that when mutated causes Long QT syndrome.

It is gratifying to see the work on precise stabilization of proteins now being translated into new therapies, said Dr. Colecraft. I look forward to working closely with the Stablix team to bring these treatments to patients.

The companys RESTORED platform has two primary components. The first is a library of binding moieties capable of recruiting selected DUBs. These recruiting moieties are conjugated with linkers to targeting ligands to create bispecific molecules that co-localize a DUB and a target. Second, a suite of biochemical and functional assays is used to monitor the ubiquitination and functional status of target proteins in cells. Stablix will initially focus pipeline development on rare diseases, oncology and immunology.

Operating plans and scientific leadership

Stablix plans to use the proceeds from the Series A financing to build out its platform and advance a portfolio of protein stabilizers towards the clinic. In addition, the company has established a lab facility in New York City, where it is building a research team led by co-founders Brian Bowman, Ph.D., head of in vitro pharmacology, and Kevin Sprott, Ph.D., head of drug discovery, with Dr. Kanner, head of platform development, leading technology transfer.

For its Scientific Advisory Board, Stablix has recruited a leading group of researchers with extensive experience in DUB biology and chemistry. In addition to Dr. Colecraft, SAB members include Benedikt Kessler, professor of biochemistry and mass spectrometry at the Target Discovery Institute, University of Oxford; Andrew Turnbull, senior principal scientist at Cancer Research UK; Chris Dinsmore, CSO at Kronos Bio; and Chris Roberts, CSO at Black Diamond Therapeutics.

Stablixs unique approach presents the company with a massive opportunity to create an impact for patients with rare diseases, cancer or immunological disorders, said Ali Behbahani, M.D., general partner at NEA and a Stablix board member. We are pleased to join this high-quality syndicate and look forward to the continued development of Stablixs platform and programs.

About Stablix Therapeutics

Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The companys RESTORED platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer and immunological disorders.

About Versant Ventures

Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firms emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $4.2 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firms founding in 1999, more than 85 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit http://www.versantventures.com.

About NEA

New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With nearly $24 billion in cumulative committed capital since the firm's founding in 1977, NEA invests in technology and healthcare companies at all stages in a company's lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 230 portfolio company IPOs and more than 390 mergers and acquisitions. http://www.nea.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005184/en/

See the original post here:
Stablix Therapeutics Launches with $63 Million Series A Financing - BioSpace

Immunology

Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting – Yahoo Finance

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, which is being held virtually from June 8-11, 2021.

Anish Suri, president and chief scientific officer of Cue Biopharma, will discuss preclinical data on CUE-401, the Companys most recent autoimmune drug product candidate. CUE-401, part of the CUE-400 series designed for differentiation and expansion of induced regulatory T cells (iTregs), is a bispecific molecule engineered to deliver the two signals, transforming growth factor beta (TGF-) and interleukin 2 (IL-2), required to induce iTregs in vivo.

Presentation DetailsSession Title: CUE-401: A Novel IL-2/TGF-beta Fusion Protein for the Induction of CD4+ FOXP3+ Regulatory T cellsPresenter: Anish Suri, Ph.D., president and chief scientific officer of Cue BiopharmaSession: Late Breaking Abstracts (Part II)Date and Time: Thursday, June 10, 2021 from 3:45 p.m. 4:00 p.m. PDT

The recorded presentation and poster will be available in the Investor & Media section of the Companys website under Scientific Publications and Presentations, following the presentation at FOCIS 2021 annual meeting.

Presentation data highlights include:

In vivo data show that CUE-401 can effectively induce FOXP3-expressing iTregs from T cells obtained from healthy donors as well as patients suffering from rheumatoid arthritis and inflammatory bowel diseases.

CUE-401 induced iTregs suppressed effector T cell responses.

A single dose of CUE-401 was shown effective at inducing Tregs in mice with active and ongoing autoimmunity.

Dr. Suri commented, We are very excited to share these promising preclinical data demonstrating CUE-401 has the ability to induce and expand regulatory T cells in vitro and in vivo. We believe this is an innovative and potentially effective means of suppressing chronic inflammatory diseases and may provide a more meaningful and lasting benefit to patients suffering from numerous autoimmune diseases, graft versus host disease (GVHD) and even transplant rejection.

About FOCIS Annual Meeting The Federation of Clinical Immunology Societies is a key forum where opinion leaders come together to chart the path to the next major breakthrough in disease therapy. Through FOCIS, researchers and clinicians share knowledge across traditional disease borders, and identify commonalities between treatments and therapies that are life-changing for those impacted by immune-mediated diseases. The FOCIS Annual Meeting educates clinicians, researchers and trainees in the broad discipline of clinical immunology. FOCIS is the worlds leader in immunology education and in training future generations of clinical immunologists. Initially established as a cross-disciplinary meeting, FOCIS held its first Annual Meeting in 2001. After two successful consecutive meetings, FOCIS was incorporated as a 501(c)3 organization in 2003. Today, FOCIS has 58 Member Societies, representing roughly 65,000 clinician scientists.

About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patients body to transform the treatment of cancer, infectious disease and autoimmune disease. The companys proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform, is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

Story continues

For more information, visit https://www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the companys estimate of the period in which it expects to have cash to fund its operations; the companys belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective engagement of disease-relevant T cells; and the companys business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the companys future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as believe, expect, may, will, should, would, could, seek, intend, plan, goal, project, estimate, anticipate, strategy, future, likely or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the companys strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the companys actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the companys limited operating history, limited cash and a history of losses; the companys ability to achieve profitability; potential setbacks in the companys research and development efforts including negative or inconclusive results from its preclinical studies, its ability to secure required U.S. Food and Drug Administration (FDA) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the companys trials; negative or inconclusive results from the companys clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the companys reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the companys ability to obtain adequate financing to fund its business operations in the future; operations and clinical the companys ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the companys most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor ContactGeorge B. Zavoico, Ph.D.VP, Investor Relations & Corporate Development Cue Biopharma, Inc. gzavoico@cuebio.com

Media ContactDarren Opland, Ph.D.LifeSci Communicationsdarren@lifescicomms.com

Originally posted here:
Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting - Yahoo Finance

Immunology

The SSC Platelet Immunology Register of VITT and VIITP: Towards standardization of laboratory and clinical parameters – DocWire News

This article was originally published here

J Thromb Haemost. 2021 Jun 2. doi: 10.1111/jth.15402. Online ahead of print.

ABSTRACT

A severe syndrome of thrombosis and thrombocytopenia has been described in patients vaccinated against severe acute respiratory distress syndrome coronavirus 2 (SARSCoV2) with a chimpanzee adenovirus vector encoding Spike protein (ChAdOx1 nCov-19, AstraZeneca).[1-6] as well as (Ad26.COV2.S, Johnson & Johnson/Janssen).[7] Currently, this novel immune thrombosis syndrome is known as vaccine-induced immune thrombotic thrombocytopenia (VITT) but has been described as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) and thrombotic thrombocytopenia syndrome (TTS) elsewhere.

PMID:34076338 | DOI:10.1111/jth.15402

More:
The SSC Platelet Immunology Register of VITT and VIITP: Towards standardization of laboratory and clinical parameters - DocWire News

Immunology

Global Precision Medicine Market, By Products and Services, – GlobeNewswire

New York, June 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Precision Medicine Market, By Products and Services, By Technology, By Application, By End User, By Region, Competition Forecast & Opportunities, 2026" - https://www.reportlinker.com/p05916716/?utm_source=GNW

Global precision medicine market was valued USD66.85 billion in 2020 and is expected to reach USD125.67 billion, growing at CAGR of 10.65% during the forecast period. Precision medicines are patient specific and vary from individual to individual. Increasing population and rising cancer cases in developing countries like India and China are the major factors propelling the growth of the precision medicine market. However, high price of precision medicines might hamper the growth of the market in the forecast period.

The global precision medicine market is segmented based on products and services, technology, application, end user, and region.The application segment is further divided into oncology, immunology, cardiology, neurology, respiratory and others.

Out of these, oncology held the largest market share in 2020 due to the increasing cases of cancer all over the world.

In terms of regional analysis, market is segregated into Asia-Pacific, North America, South America, Middle East & Africa and Europe.Among these, North America dominated the global precision medicine market until 2020 due to growing adoption of next generation sequencing methods in addition to favorable government policies.

Additionally, Asia-Pacific is anticipated to grow at the fastest CAGR due to the rising cases of cancer and other fatal diseases in the developing economies like India and China.

Major players in the global precision medicine market include IBM Watson Group, Roche Holding AG, Thermo Fischer Scientific Inc., Philips Healthcare Ltd., Illumina Inc., Quest Diagnostics Inc., Qiagen NV, AstraZeneca Plc, Agilent Technologies Inc., Novartis AG, NanoString Technologies Inc., NantHealth Inc., Orion Health Inc., Celcuity Inc., InsightRX Inc., and others. The companies are adopting various organic and inorganic strategies like, product launches, acquisitions and mergers to strengthen their position in the market. On 15th April 2021, Agilent Technologies, Inc. completed the acquisition of Resolution Bioscience, which is a leader in the development and commercialization of next-generation sequencing (NGS) based precision oncology solutions. Resolution Bioscience complements and expands Agilents capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market. Moreover, the addition of Resolution Biosciences liquid biopsy-based diagnostic technologies strengthens Agilents offerings to biopharma and clinical diagnostics customers and boosts growth opportunities in the companys diagnostics and genomics business.

Years considered for this report:

Historical Years: 2016-2019Base Year: 2020Estimated Year: 2021Forecast Period: 20222026

Objective of the Study:

To analyze historical growth in market size of global precision medicine market from FY2016 to FY2020. To estimate and forecast the market size of global precision medicine market from FY2021 to FY2026 and growth rate until FY2026. To classify and forecast global precision medicine market based on products and services, technology, application, end user, and region. To identify drivers and challenges for global precision medicine market. To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global precision medicine market. To conduct pricing analysis for global precision medicine market. To identify and analyze the profile of leading players operating in global precision medicine market.The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of manufacturers across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the manufacturers which could not be identified due to the limitations of secondary research. The analyst examined the manufacturers, distribution channels and presence of all major players across the globe.The analyst calculated the market size of global precision medicine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and Application for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

Precision medicine manufacturers, suppliers, distributers and other stakeholders Government bodies such as regulating authorities and policy makers Organizations, forums and alliances related to precision medicine Market research and consulting firmsThe study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global precision medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below: Global Precision Medicine Market, By Products and Services:o Precision Medicine Platformso Precision Medicine Toolso Precision Medicine Services Global Precision Medicine Market, By Technology:o Big Data Analyticso Artificial Intelligenceo Bioinformaticso Whole Genome Sequencingo Companion Diagnosticso Next Generation Sequencing (NGS)o Others Global Precision Medicine Market, By Application:o Oncologyo Immunologyo Cardiologyo Neurologyo Respiratoryo Others Global Precision Medicine Market, By End User:o Pharmaceutical and Biotechnology Companieso Healthcare ITo Diagnostic Companieso Clinical Research Organizationo Research Institutes Global Precision Medicine Market, By Region:o North AmericaUnited StatesCanadaMexicoo EuropeGermanyUnited KingdomFranceItalySpaino Asia-PacificChinaIndiaJapanSouth KoreaAustraliaSingaporeo South AmericaBrazilArgentinaColombiao Middle East & AfricaSouth AfricaSaudi ArabiaUAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global precision medicine market.

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five)Read the full report: https://www.reportlinker.com/p05916716/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more from the original source:
Global Precision Medicine Market, By Products and Services, - GlobeNewswire

Physiology

AU research: Switching to plant-based diet protects against heart disease – The Augusta Chronicle

Cutting out animal protein in favor of a plant-based diet appears to change the makeup of bacteria in the gut and helps protect against salt-related heart disease, new research at Augusta University found. It also protected against a serious complication in pregnancy and the effect seems to be passed down to offspring, the researchers found.

The discovery in rats was actually unintended and came about because the researchers years ago were trying to find a more affordable feed for them, said Dr. David Mattson, chair of the Department of Physiology at Medical College of Georgia at AU. He and his colleagues were working with a rat specially bred to be sensitive to salt and to develop heart disease when fed a high-salt diet.

"They will start to develop cardiovascular disease," Mattson said. "They will start having heart failure, they will start having strokes. If we dont do something for them quite quickly, they will start to die, which completely parallels what is observed in salt-sensitive humans."

But when they switched the rats from a diet whose protein contained casein, a protein found in milk, to one with a wheat gluten protein, the animals didn't respond as they normally would. The researchers confirmed this by comparing the same type of rat fed the animal-protein diet to the grain-fed diet, said Dr. Justine Abais-Battad, an instructor in Physiology and lead author on the study in the journal Acta Physiologica.

The grain-fed rats "still are ingesting the same amount of salt but werent salt-sensitive any more," she said, while those on the animal protein diet developed heart disease and kidney damage, as expected.

The animals appear to have different bacteria in their guts as a results of the switch, a change in what is called the microbiome,Abais-Battad said.

"What Justine has shown here is this big switch in the microbiome," Mattson said, which are millions of different bacteria that help humans break down and digest food and perform other basic functions related to health. Unhealthy colonies of bacteria can lead to disorders such as irritable bowel syndrome, constipation and other problems, said Dr. Satish Rao, chief of gastroenterology and director of the Digestive Health Center at AU Health System.

But the diet switch also appears to have an effect in preeclampsia, Mattson said, a serious and potentially deadly complication in pregnancy where women develop high blood pressure and can have damage to the kidneys and liver. Post-doctoral fellow John Henry Dasinger's work showed that those fed the grain-based diet were protected while death "in these pregnant female rats was tremendous when fed the disease-promoting diet," Mattson said. That study was published in the journal Pregnancy Hypertension.

The takeaway from this is what people have been hearing all along, Abais-Battad said.

"People already know that these types of habits, these healthier choices would be protective" against heart disease, she said.

Interestingly, offspring from parents fed the grain-based diet also appear to have the protective effect even when fed the animal protein diet, Abais-Battad said.

"Even though all of the offspring were fed the same disease-promoting diet,those who came from the grain-fed parents, we actually saw a reduction in their disease over time," she said. The theory is they have inherited the bacterial makeup, the microbiome, from the parents, most likely Mom, Abais-Battad said.

"Theres a lot of literature demonstrating the transmission of microbiome from Mom to baby," she said. "We do think that likely is playing a big role in programming the offspring."

The question now becomes what the mechanism are behind the beneficial effect from the bacterial changes, Mattson said. The more beneficial bacteria produce different byproducts and those byproducts or metabolites "are really the key to whats happening downstream," he said. "So we are working to identify those molecules and how those molecules influence the biological function."

Being able to manipulate the microbiome has been the aim of a lot of research, Rao said.

"The big challenge, which has not been overcome to the best of my knowledge, is how do we change the gut microbiome?" he said.

Many of those efforts or interventions come after the person has already developed disease that might have its roots in earlier life, such as in obesity, Rao said.

"I think that is too late in the game," he said. "We need to really catch these youngsters, adolescents and so on, really at the very early stages."

In the case of the rat offspring, that will "start at the very beginning," Abais-Battad said.

View original post here:
AU research: Switching to plant-based diet protects against heart disease - The Augusta Chronicle

Physiology

Electromedical Technologies and Nazarbayev University Complete Agreement to Expand Promising Joint Research Programs – BioSpace

SCOTTSDALE, Ariz., June 3, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, is pleased to announce that the Company recently completed an agreement with Nazarbayev University to expand its Stage I collaborative research programs. These Stage I programs will study how electro-modulation communicates to cells by modifying intracellular signaling events and altering physiological cellular response.

Electro-modulation therapies (electroceuticals) are conducted and widely applied in medicine today utilizing a variety of frequencies to reduce chronic pain. A front page TIME magazine article noted: "Electroceuticals "are the next wave of new treatments we will have to treat disease," says Kris Famm, president of Galvani Bioelectronics, a biotech collaboration between Glaxo-Smith-Kline and Google's Verily that is focused on developing electricity-based therapies (https://time.com/5709245/bioelectronic-medicine-treatments/). Going forward, researchers hope to learn how alternating electrical fields affect cell physiology and induce their effects.

The main challenge is to define specific electrical frequencies that alter cell physiology by modulating the body's cellular signaling network. Deciphering the impacts of alternating electrical fields on cell signaling will build a solid platform for the development of novel non-invasive technologies in medicine. Once this process is unlocked, leading bioelectronic producers such as Electromedical Technologies could develop new, highly effective, and application/condition-specific devices for broad consumer use.

Matthew Wolfson, Founder and CEO of Electromedical Technologies, noted, "Unraveling the codes of electro-modulation controlling cell behavior will be instrumental in developing effective and targeted applications of the next generation of bioelectronic devices. Thus, decoding the language of electro-modulation is a focus of our research team spearheaded by Professor Dos Sarbassov at Nazarbayev University. We are pleased to be working together on these promising studies that could have a favorable impact on human health using physics instead of drugs."

Dr. Sarbassov is a prominent expert in cell signaling, who received an intensive postdoctoral research training at MIT's Whitehead Institute for Biomedical Research and worked for many years as a Faculty Member of the Molecular and Cellular Oncology Department at MD Anderson Cancer Center. He joined Nazarbayev University in 2019 to contribute to a scientific development of the country of his origin. In 2020, Dr. Sarbassov became a Director of the National Laboratory Astana (NLA), a leading research organization at Nazarbayev University.

Dr. Dos Sarbassov commented, "Our work with the Electromedical Technologies is a great collaborative effort of an academic institution with private industry. This joint focus is on advancing technology by understanding the mechanisms of electrical communication with cell physiology. Our primary initial goal is to study and determine how cells react to alternating electrical fields by analyzing their effects on cell signaling and by translating how they lead to distinct responses of cells and tissues."

Matthew Wolfson commented further, "We seek to utilize the deciphering of the mechanisms of electrical signaling on cells in an effort to provide a solid foundation in our development of effective treatments of inflammation, neurodegenerative disorders and opioid addiction. With the new agreement and program parameters in place, the Company and the University look forward to commencing the IDE (Investigational Device Exemption) process leading to a submission with the FDA."

About Nazarbayev University:

Nazarbayev University (NU), established on the initiative of the first President of the Republic of Kazakhstan in 2010, is the country's flagship academic institution with aspirations to become a global-level research university. This is the first university in Kazakhstan which is guided by the principles of autonomy and academic freedom. Located in the capital of Kazakhstan, NU is a research university with growing international renown combining education, research and innovation on a state of the art 21st-century campus. NU scholars conduct research in many fields, and seek to expand human knowledge through innovation, analysis, and collaboration. Within ten years since its inception, NU has become a leading research university in Kazakhstan. NU research is supported by the government of the Republic of Kazakhstan, local and international organizations, and is carried out in the Schools, Research Centers and Institutes. Please visit Nazarbayev University website https://research.nu.edu.kz/en/ to find comprehensive information on the NU research activities and profiles of faculty and researchers.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief. For more information, please visit http://www.electromedtech.com. Nonhuman preliminary studies that we are planning to start in the near future and their applications are not related to our current product in any way and currently not cleared in the US.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Corporate Contact:

Electromedical Technologies, Inc.Hanover InternationalTel: 1.888.880.7888email: ir@electromedtech.comhttps://electromedtech.com

View original content:http://www.prnewswire.com/news-releases/electromedical-technologies-and-nazarbayev-university-complete-agreement-to-expand-promising-joint-research-programs-301304872.html

SOURCE Electromedical Technologies, Inc.

Company Codes: OTC-PINK:EMED, OTC-QB:EMED, OTC-QX:EMED

Link:
Electromedical Technologies and Nazarbayev University Complete Agreement to Expand Promising Joint Research Programs - BioSpace